To continue the innovations on Financial Orbit I would like to introduce a second guest author. Harsha Boralessa
is a CFA charterholder and a chartered accountant. He has several years of
professional experience working with investments involving equity, fixed income,
derivatives and private equity in a number of organisations including a
European bank, a global asset management company and global accounting firms.
He is interested in fundamental bottom-up value investing and how investors' behaviour
may create opportunities where an equity's market price will differ significantly
from its intrinsic value. Having
previously invested mainly in Funds, he is starting to invest in individual
equities and as part of the process of developing his investment style, he has contributed
the following piece.
'GlaxoSmithKline - is there
value?' by Harsha Boralessa
After the bump in the share price of GlaxoSmithKline (GSK) following the announcement of its transaction
with Novartis last April, GSK's share
price has declined by approximately 14%, as of 22nd August 2014 and the last time
that the price reached this level was in January 2013.
GSK has also underperformed the FTSE 100 by approximately 19% in the last year.
The question is whether this is a temporary blip and GSK is a potential value opportunity or
is this the start of a long term decline?
GSK has suffered damaging
headlines relating to China involving the trial of two private investigators connected
to a scandal involving a top executive of the company. Unfortunately for the company investigations
continue in country. According to the GSK's Q2 2014 press release, Pharmaceuticals
and Vaccines sales in China including Established Products fell by 22% to £267
million in H1 2014, which is approximately 3% of total Pharmaceuticals and
Vaccines sales of £9,025 billion.
Despite recent bad headlines China is still potentially a
huge market for GSK but a far more pressing issue appears to be falling sales
in its Pharmaceuticals division as shown below. The table below and others in
this report have been sourced from GSK's
Q2 2014 press release, except where stated.
The falling pharmaceutical sector sales are being driven by
the decline of Respiratory sales (see below) due to increased competition, in
particular Advair/ Seretide sales. In
H1 2014, Advair/ Seretide accounted
for almost 69% of Respiratory and almost 39% of Innovative Pharmacuticals. The key issue is how much the new Respiratory
products such as Relvar/ Breo and Anoro will make up the decline, currently
their sales are relatively small.
GSK's Established
Products sales have also been hit hard.
In particular Lovaza's sales, which is being impacted by generics, have
declined by 81% in Q2 2014 to £27 million.
Many of these issues are contributing to falling sales in
the United States where general generic pricing pressures are also impacting
more materially:
Unsurprisingly this sales decline has also been reflected by
declines in core operating profit and margins again mainly driven by
significant falls in the Pharmaceuticals division specifically and the US
geographically.
Clearly, GSK is
facing some fundamental issues, which GSK's
CEO, Sir Andrew Witty summarised in this comment during the Q2 2014 earnings
call: "As you know our strategy over
the last six years has been to fundamentally reshape the Group and our R&D
operations in particular, so that we can replace the significant sales we lost
to generics and ensure that the Company can succeed in an environment where our
biggest product Advair faces increasing competition".
So what is being done to address this? The Novartis deal, if approved, should
bring significant growth in Vaccines through the acquisition of Novartis's global Vaccines business
(excluding flu) and Consumer Healthcare, by creating the second largest
Consumer Healthcare company (by revenue) in the world, which GSK would control and have a 63.5%
stake, see slide below from the GSK
presentation in April 2014.
This would reduce the reliance on Pharmaceutical sales and
help in having broader sources of revenue growth, see slide below from the GSK presentation in April 2014.
It is also anticipated that £4 billion of capital would be
returned in the form of a B share transaction, following the completion of the Novartis transaction, which is
approximately 6% of the market capitalisation of GSK as of 22nd August 2014.
Furthermore, the Vaccines division (4%) and HIV sales (9%)
continue to grow in H1 2014. The sales
of new pharmaceuticals and vaccine launches in the last 5 years (2010 to 2014
inclusive) was £565 million in H1 2014, a growth of 73%. According to GSK, there is a substantial development
pipeline with over 40 new molecular entities (NMEs) in late stage development.
In terms of valuation,
GSK is trading at around 13x EV/ EBIT (TTM), which is at the lower end of its
pharma peer group. GSK is also trading at a Free Cash Flow yield of around 6% (TTM),
which is at the higher end of its pharma peer group. Although GSK's
net debt has risen to £14.4 billion since the end of 2013 giving it a net debt/
EBITDA ratio of around 1.6x, which is at the higher end of its pharma peers,
this does not appear to be excessive as GSK
has a history of generating good free cash flow.
GSK's management
have a good track record of returning capital to shareholders through dividends
and significant share buy-backs. The
dividend has increased by over 6% on an annualised basis over the last 5 years,
although revenue and earnings have grown more slowly. The dividend yield is
around 5.5% (TTM) and the dividend should be sustainable given GSK's strong cash flow generation and
not excessive debt. Overall, there has
been an approximately 8% return of capital to shareholders per annum between
2011 and 2013 based on the average market capitalisation of GSK.
In the Q2 2014 earnings call, the GSK CEO, Sir Andrew Witty observed "the dividend remains our priority in terms of shareholder
distributions. There is no change to the policy. Over the last couple of years,
we have been paying out relatively high amounts as we go through this
transition period and clearly decisions for the future for the Board of the
time. But I think we have laid out our store on that front and there is no
change in the policy"
Although there is uncertainty about GSK's future prospects with Respiratory and US sales, there do seem
to be some positive signs, including the refocusing of the business with the Novartis deal. I would consider buying GSK in the low to mid 1300s and would review at 1500p, whilst
enjoying the dividends and other shareholder remuneration in the interim.
(Please note that all views are Harsha's and do not represent any form of investment advice. He does not have any direct equity holdings in GlaxoSmithKline, however the Funds in which he invests may have holdings).








No comments:
Post a Comment